Reported about 24 hours ago
J.P. Morgan has reiterated its Hold rating on Johnson & Johnson (JNJ), setting a price target of $185. Analyst Chris Schott pointed out the company's strong potential for over 5% growth through its innovative offerings, but he also raised concerns regarding sales erosion from biosimilars and ongoing talc litigation. Overall, while Schott remains cautiously optimistic, he indicated that some AI stocks might offer better investment prospects.
Source: YAHOO